Followed the successful launch of Firebird 2 (Rapamycin-Eluting Coronary CoCr Stent System) in the domestic market earlier this year, The 2nd generation of MicroPort's drug eluting stent was introduced to Thailand by Thai Otsuka Pharmaceutical Co., Ltd. on 17th Oct. 2009. This is the first time that Firebird 2 becomes available in the international markets.
More than a hundred guests, including interventional cardiologists, nurses and industrial professionals attended The Grand Opening Ceremony that was held in J.W. Marriot in Bangkok. Mr. Yoosik Choi, president of Thai Otsuka Pharmaceutical and Mr. Philip Wang, CMO of MicroPort Medical and some of the most renowned Thai cardiologists were also on the guest list. Mr. Choi delivered an opening speech for an official start for the ceremony.
In addition, A Registry Summit was organized before the ceremony. In the meeting Dr. Damras from Siriraj Hospital, Dr. Paiboon from Vajira Hospital, Dr. Dilok from Thammasart Hospital and Dr. Kriengkrai from Chest Disease Institute shared up-to-date clinical results of Firebird Registry at their local hospitals to the audience. They spoken highly about the product performance and also expressed great confidence about the positive outcomes for long-term results.
With the brilliant market performance of Firebird in Thailand since 2006, we truly believe that Firebird2 will meet the expectation of interventional specialists and surely will help to improve patients' life quality.